In this study, researchers investigated the potential use of all-trans retinoic acid (ATRA) as a therapeutic option for gastric cancer. They evaluated the anti-proliferative effects of ATRA in gastric cancer cell lines and tissue samples, and performed RNA-sequencing studies to analyze the gene networks and molecular mechanisms underlying ATRA’s anti-tumor activity. The results showed that approximately half of the cell lines were sensitive to ATRA, and a model consisting of 42 genes was constructed to predict ATRA sensitivity in gastric cancer. Additionally, ATRA was found to have immune-modulatory effects, suggesting potential combination therapies with immune checkpoint inhibitors. These findings lay the foundation for further clinical trials and personalized treatment strategies for gastric cancer.
https://pubmed.ncbi.nlm.nih.gov/37951921/